Benjamin F. Edwards & Company’s Seres Therapeutics MCRB Stock Holding History

Benjamin F. Edwards & Company’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-68	Closed	-$4K	–	1917
2019 Q2	$4K	Hold	68	–	–	﹤0.01%	1684
2019 Q1	$9K	Hold	68	–	–	﹤0.01%	1351
2018 Q4	$6K	Hold	68	–	–	﹤0.01%	1409
2018 Q3	$10K	Hold	68	–	–	﹤0.01%	1272
2018 Q2	$12K	Hold	68	–	–	﹤0.01%	1229
2018 Q1	$10K	Buy	68 +41	+152%	+$7.86K	﹤0.01%	1262
2017 Q4	$5K	Hold	27	–	–	﹤0.01%	1363
2017 Q3	$9K	Hold	27	–	–	﹤0.01%	1193
2017 Q2	$6K	Buy	+27	New	+$5.54K	﹤0.01%	1204

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Benjamin F. Edwards & Company's MCRB Position: Q3 2019 in Review

Benjamin F. Edwards & Company sold out of Seres Therapeutics (MCRB) in Q3 2019, closing a stake of 68 shares — an estimated $4K sold.

Benjamin F. Edwards & Company first reported a position in MCRB in Q2 2017 and held it in 9 quarters. The position peaked at $12K in Q2 2018. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2019.

Benjamin F. Edwards & Company reported no remaining Seres Therapeutics position as of Q3 2019 after selling out during the quarter.
Benjamin F. Edwards & Company sold 68 Seres Therapeutics shares in Q3 2019, an estimated $4K.
Benjamin F. Edwards & Company first reported a position in Seres Therapeutics in Q2 2017 and held it in 9 quarters.
Benjamin F. Edwards & Company's Seres Therapeutics position peaked at $12K in Q2 2018.
77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2019.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2019, filed 5 Nov 2019.